Live Breaking News & Updates on Editas medicine investor relations

Stay updated with breaking news from Editas medicine investor relations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Editas Medicine Announces Transition of Chief Scientific Officer

Editas Medicine Announces Transition of Chief Scientific Officer
Editas Medicine Announces Transition of Chief Scientific Officer
CAMBRIDGE, Mass., Jan. 11, 2021 — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity. A search is underway to find a successor to Dr. Albright.
“On behalf of the entire Editas team, I sincerely thank Charlie for his many contributions in pioneering the field of genomic medicine. Charlie has been instrumental in building our scientific organization, defining our programs, and advancing our pipeline. We wish him all the best as he pursues his new role,” said Cindy Collins, President and Chief Executive Officer, Editas Medicine.

Cambridge , Cambridgeshire , United-kingdom , Charles-albright , Cindy-collins , Cristi-barnett , Exchange-commission , Company-on , Editas-medicine-inc , Nasdaq , Editas-medicine , Chief-scientific-officer

Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors

Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors
marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.

Ahmedabad , Gujarat , India , Cambridge , Cambridgeshire , United-kingdom , Meeta-chatterjee , Cristi-barnett , Jamesc-mullen , Alliance-management , Xavier-university , University-of-virginia-school-medicine